Mitragynine obtient la FDA IND, ouvrant la voie à l'essai sur les opioïdes

Mitragynine, the main psychoactive compound in kratom, just cleared the FDA IND hurdle, opening the door for the first human safety study.

From Lab to Clinic

NIH and the University of Florida engineered a purified mitragynine formulation and performed preclinical work that proved the compound’s safety across several doses in animal models. The IND, approved on June 1, 2026, signals that the FDA accepts the data and allows investigators to move into human testing.

What the IND Means

With the IND in effect, researchers can launch a phase‑I trial that will be randomized, double‑blind, and placebo‑controlled. The study will evaluate safety and tolerability in people with opioid use disorder, a population that has suffered historically high overdose mortality.

Next Steps in the HEAL Initiative

The trial is part of the Helping to End Addiction Long‑term® Initiative (HEAL Initiative), a federal effort to expand treatment options. If mitragynine proves safe, it could become a new tool for recovery and help shift the current opioid treatment paradigm.

Why This Matters

Kratom’s popularity as a self‑medication for opioid withdrawal has surged, yet no isolated compound has been rigorously tested in humans. NIH’s IND approval removes a major regulatory barrier, allowing the scientific community to finally assess whether mitragynine’s slow conversion in the body can translate into clinical benefit.

Looking Ahead

The upcoming trial will provide the first human data on mitragynine’s pharmacokinetics and safety profile. Positive results could spur larger efficacy studies and potentially add a novel, plant‑derived option to the opioid treatment arsenal.

Source: NIH research clears way for study of experimental treatment for opioid use disorder
Domain: nih.gov